Skip to main content

Human stem cell applications for the treatment of hearing loss

Objective

Hearing impairment is the most frequent human sensory deficit and is mainly caused by the irreversible loss of neurosensory cells in the cochlea. The lack of human otic cell models represents a significant roadblock that has hampered the development of drug-based or cell-based therapies for the treatment of hearing loss. In a collaborative effort under this proposal we wish to devise approaches to generate human otic progenitors and differentiated otic cells from different human stem cell sources. We have devised guidance protocols for mouse and human embryonic and reprogrammed stem cells toward inner ear cell types that make use of principles of early germ layer formation and otic induction. A limitation is the efficacy of otic progenitor cell generation. Purification techniques for human otic progenitors from ES/iPS cell sources and in addition from native human otic tissues from fetal and adult stages will will serve the dual purpose for one to enable the development of novel bioassays for drug screens, as well as generating cells with decreased tumorigenicity for cell transplantation studies in in vivo animal models. New hit compounds identified from screening efforts will be tested and validated further in established organ culture models. The identification of relevant candidate compounds will be further developed as lead drug candidates in noise and ototoxic drug induced in vivo models. The scope of this stem cell technology development requires a collaborative team effort, with groups that have substantial combined experience in human ES/iPS cell work, inner ear stem cell biology, high-throughput assay development, and in translating research findings into the clinic as well as into the biotechnology realm. Within the consortium there exists an established translational route from bench to bedside for the commercial development of human otic stem cell derived technology towards inner ear medical applications aiming at the restoration of hearing function.

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Coordinator

EBERHARD KARLS UNIVERSITAET TUEBINGEN
Address
Geschwister-scholl-platz
72074 Tuebingen
Germany
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 931 165
Administrative Contact
Hubert Löwenheim (Prof.)

Participants (9)

UNIVERSITAET BERN
Switzerland
EU contribution
€ 645 649,50
Address
Hochschulstrasse 6
3012 Bern
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Pascal Senn (Dr.)
THE UNIVERSITY OF SHEFFIELD
United Kingdom
EU contribution
€ 627 359,50
Address
Firth Court Western Bank
S10 2TN Sheffield
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Joanne Watson (Mrs.)
UNIVERSITE D'AIX MARSEILLE
France
EU contribution
€ 563 589,50
Address
Boulevard Charles Livon 58
13284 Marseille
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Celine Damon (Ms.)
UPPSALA UNIVERSITET
Sweden
EU contribution
€ 488 542,50
Address
Von Kraemers Alle 4
751 05 Uppsala
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Siv Utterberg (Mrs.)
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
United States
EU contribution
€ 644 839
Address
Serra Mall 450
94305 2004 Stanford
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Alfred Machicado (Mr.)
MASSACHUSETTS EYE AND EAR INFIRMARY
United States
EU contribution
€ 619 839
Address
Charles Street Suite 421 243
02114 Boston
Activity type
Research Organisations
Administrative Contact
Albert Edge (Dr.)
AUDION THERAPEUTICS BV
Netherlands
EU contribution
€ 712 000
Address
Linnaeusparkweg 10-2
1098 EA Amsterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Rolf Jan Rutten (Mr.)
ACOUSIA THERAPEUTICS GMBH
Germany
EU contribution
€ 606 800
Address
Sindelfinger Strasse 3
72070 Tubingen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Frank Kalkbrenner (Dr.)
SCIPROM SARL
Switzerland
EU contribution
€ 160 000
Address
Rue Du Centre 70
1025 Saint Sulpice
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Kirsten Leufgen (Dr.)